SBIR/STTR Research Award

Lactoferrin Modulation of Granuloma Pathology

Award identifier c1a0ecae6d57e6a7f55eb95a17f36241da060e78456175452a5e99ea21f389d0Awarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$224,725

Program and phase

STTR · Phase I

Award year

2015

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
Pharmareview Corporation
Proposal award date
2015-02-15
Contract end date
2016-01-31
UEI
D9MKKSEF5EC1
Solicitation number
PA14-072
Topic code
NIAID

Research abstract

DESCRIPTION provided by applicant Host immunity plays a major role in development of Tuberculosis disease Tuberculosis infected individuals respond by formation of granulomas which contain bacilli However organisms within granulomas are protected from the full scope of immune mediated defenses We hypothesize that modulation of destructive immune mediated pathology while preserving essential immune responses will allow more effective immune control The goal of these studies is therefore to assess bioactivity of novel recombinant mouse and human lactoferrins for use as immune modulators to ameliorate granuloma pathology Our aims are to determine lactoferrinandapos s ability to limit destructive pathology and to evaluate its immune modulatory effects in the cord factor glycolipid trehalose andapos dimycolate TDM model of tuberculosis granulomatous response To accomplish our goal mice will be challenged iv with TDM and then treated with lactoferrin via oral or iv route hours later Lung tissue will be evaluated through day post TDM administration for changes in histology and inflammatory mediators Immunopathology will be compared between mice given bovine lactoferrin or novel recombinant CHO derived mouse or human lactoferrins These studies will evaluate bioactivity of oral and intravenous delivered novel recombinant mouse lactoferrin for use as a preclinical research tool in a mouse homologous system to alter granuloma responses validate the mouse as a species to examine activity of heterologous recombinant human lactoferrin to alter pathology to tuberculosis related factors and compare responses of both novel lactoferrins to bovine lactoferrin which is not acceptable as an injectable human clinical therapeutic to achieve confidence to move forward with Phase II testing and challenge using virulent M tuberculosis Overall this approach represents a novel therapeutic strategy for potential treatment of tuberculosis disease PUBLIC HEALTH RELEVANCE Host immunity plays a major role in development of Tuberculosis disease Infected hosts respond by the formation of granulomas which help to contain the bacilli However organisms within granulomas are protected from the full scope of immune mediated defenses Modulation of immune mediated destructive pathology while preserving essential immune responses will allow more effective immune control These studies will capitalize on our experience using novel recombinant mouse and human lactoferrins as immune modulators to ameliorate granulomas in a TB induced pathology model offering a novel therapeutic strategy for treatment of tuberculosis disease

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Awards with the same topic code

Verified by an exact topic code match. This is not a text-similarity match.

Research funding history

8 SBIR/STTR records share this UEI (2002–2017). Reported award amounts total $7,187,054. Reported amounts are not federal obligations.

Phases: Phase II, Phase I

Agencies: Department of Health and Human Services

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.